Results 301 to 310 of about 88,529 (348)
Some of the next articles are maybe not open access.
Denosumab: Anti-RANKL antibody
Current Osteoporosis Reports, 2009Denosumab (anti-receptor activator of nuclear factor-kappaB ligand antibody) is a novel agent, a fully human monoclonal antibody that inhibits osteoclastic-medicated bone resorption by binding to osteoblast-produced RANKL. By reducing RANKL binding to the osteoclast receptor RANK, bone resorption and turnover decrease.
openaire +2 more sources
Nihon rinsho. Japanese journal of clinical medicine, 2005
A therapeutic vaccine approach, targeting RANKL, can be used to inhibit bone destruction in pathological bone loss conditions such as osteoporosis, rheumatoid arthritis and bone metastasis. Compared to other therapeutic recombinant protein against pathological antigen such as monoclonal antibodies, soluble receptor or other antagonists, a vaccine needs
Takuo, Juji, Sakae, Tanaka
openaire +1 more source
A therapeutic vaccine approach, targeting RANKL, can be used to inhibit bone destruction in pathological bone loss conditions such as osteoporosis, rheumatoid arthritis and bone metastasis. Compared to other therapeutic recombinant protein against pathological antigen such as monoclonal antibodies, soluble receptor or other antagonists, a vaccine needs
Takuo, Juji, Sakae, Tanaka
openaire +1 more source
Science Signaling, 2009
RANKL-RANK signaling mediates the central fever response to inflammatory cytokines and plays a role in female thermoregulation.
openaire +1 more source
RANKL-RANK signaling mediates the central fever response to inflammatory cytokines and plays a role in female thermoregulation.
openaire +1 more source
RANKL and osteoimmunology in periodontitis
Journal of Bone and Mineral Metabolism, 2020Periodontitis, one of the most common infectious diseases in humans, is characterized by inflammation of the periodontal tissue and subsequent destruction of the alveolar bone, which ultimately leads to tooth loss. Recently, it was revealed that the osteoclastic bone damage that occurs during periodontitis is dependent on the receptor activator of NF ...
openaire +2 more sources
2018
?????????????????? ???????????????? ??????????????????????, ?????????????????? ?????????????????????? ???????????????? ?????????? (??????), ?????????????????????????????? ?????????????????????? ?? ???????????????????? ?????????????????????????????? ?????????????? ??????????. ?????????????????????????? ???????????????????????????????? ?????? ????????????
openaire +1 more source
?????????????????? ???????????????? ??????????????????????, ?????????????????? ?????????????????????? ???????????????? ?????????? (??????), ?????????????????????????????? ?????????????????????? ?? ???????????????????? ?????????????????????????????? ?????????????? ??????????. ?????????????????????????? ???????????????????????????????? ?????? ????????????
openaire +1 more source
Nihon rinsho. Japanese journal of clinical medicine, 2016
RANKL (receptor activator of nuclear factor-κB ligand) critically regulates the differentiation, activation, and survival of the osteoclast, and the hyperactivation of the RANKL-RANK signaling pathway leads to osteoporosis. Denosumab is a complete human monoclonal antibody against human RANKL, and suppresses bone resorption by inhibiting the ...
Toshinobu, Omiya, Sakae, Tanaka
openaire +1 more source
RANKL (receptor activator of nuclear factor-κB ligand) critically regulates the differentiation, activation, and survival of the osteoclast, and the hyperactivation of the RANKL-RANK signaling pathway leads to osteoporosis. Denosumab is a complete human monoclonal antibody against human RANKL, and suppresses bone resorption by inhibiting the ...
Toshinobu, Omiya, Sakae, Tanaka
openaire +1 more source